GlassScriptPhysician profile
Tetyana Roytman
NPI 1982249868
$5,590.05
in general payments reported to CMS, 2019-2025
33 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,373 · 2022: $1,352 · 2023: $1,852 · 2024: $817 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,865.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,119.82 | 2021-2025 | |
| Ucb, INC. | $603.04 | 2021-2024 | Briviact |
| Sk Life Science, INC. | $398.14 | 2021-2024 | Xcopri |
| Arbor Pharmaceuticals, INC. | $365.29 | 2021-2022 | |
| Allergan, INC. | $338.06 | 2021-2022 | |
| Biogen, INC. | $275.69 | 2021-2023 | Vumerity, Tysabri |
| Harmony Biosciences LLC | $273.80 | 2022-2024 | Wakix |
| Scilex Pharmaceuticals INC. | $270.61 | 2021-2023 | Ztlido |
| Neurocrine Biosciences, INC. | $249.21 | 2021-2024 | Ingrezza |
| Azurity Pharmaceuticals, INC. | $244.09 | 2023-2024 | Horizant, Horizant |
| Lilly USA, LLC | $203.95 | 2022-2024 | Emgality, Reyvow, Amyvid |
| Otsuka America Pharmaceutical, INC. | $149.70 | 2023-2024 | Rexulti, Nuedexta |
| Amneal Pharmaceuticals LLC | $144.06 | 2022-2023 | Rytary |
| Eisai INC. | $117.32 | 2022-2024 | |
| Lundbeck LLC | $106.21 | 2023-2024 | Vyepti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $94.12 | 2021-2023 | Valtoco |
| Avanir Pharmaceuticals, INC. | $86.00 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $81.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.40 | 2022-2024 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $59.41 | 2021-2023 | Austedo Xr |
| Sumitomo Pharma America, INC. | $45.59 | 2023 | Aptiom |
| Genzyme Corporation | $39.96 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $37.33 | 2023-2025 | Zoryve, Seglentis |
| Amgen INC. | $25.00 | 2022 | |
| Kyowa Kirin, INC. | $24.87 | 2024 | Nourianz |
| Genentech USA, INC. | $23.18 | 2023 | Ocrevus |
| Pfizer INC. | $21.61 | 2024 | |
| Merck Sharp & Dohme LLC | $21.49 | 2025 | Verquvo |
| Biohaven Pharmaceutical Holding Company LTD. | $21.10 | 2022 | |
| Bausch Health US, LLC | $20.21 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.77 | 2021 | |
| Boston Scientific Corporation | $16.50 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tetyana Roytman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.